Literature DB >> 87556

Carnitine deficiency induced during intermittent haemodialysis for renal failure.

T Bohmer, H Bergrem, K Eiklid.   

Abstract

Carnitine concentration was measured in plasma, muscle, and dialysate before and after haemodialysis in patients with renal failure and in plasma and muscle of healthy controls. In eight of the nine patients carnitine concentration in muscle after haemodialysis was only 10% of the concentration in controls. Plasma-carnitine varied in patients before dialysis and in all of them was reduced by dialysis. The loss of carnitine into the dialysate (190--2100 mumol/treatment) greatly exceeded the normal loss in urine for most of patients, and was only partly compensated for. In some patients normal or high plasma-carnitine and low concentrations in muscle indicated that the carnitine-concentrating mechanisms in the muscle cell had failed. The reduction in carnitine will interfere seriously with normal cellular functions and this may help to explain the clinical syndrome of cardiomyopathy and cardiac failure which has been observed in some patients treated for a long time with intermittent haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 87556     DOI: 10.1016/s0140-6736(78)90422-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  Potential role of carnitine in patients with renal insufficiency.

Authors:  C Wanner; W H Hörl
Journal:  Klin Wochenschr       Date:  1986-07-01

Review 2.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

Review 3.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

Review 4.  Influence of vasospasm on visual function.

Authors:  P Gasser; J Flammer
Journal:  Doc Ophthalmol       Date:  1987-05       Impact factor: 2.379

Review 5.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

6.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

7.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

8.  Fatal lipid storage myopathy with deficiency of cytochrome-c-oxidase and carnitine. A contribution to the combined cytochemical-finestructural identification of cytochrome-c-oxidase in longterm frozen muscle.

Authors:  J Müller-Höcker; D Pongratz; T Deufel; J M Trijbels; W Endres; G Hübner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

9.  [Serum levels and urine excretion of L-carnitine in patients with normal and impaired kidney function].

Authors:  M Leschke; K W Rumpf; T Eisenhauer; K Becker; U Bock; F Scheler
Journal:  Klin Wochenschr       Date:  1984-03-15

10.  "Carnitine deficient" myopathy and cardiomyopathy with fatal outcome.

Authors:  F Cornelio; S Di Donato; D Testa; M Mora; G Gori; D Peluchetti; M Rimoldi
Journal:  Ital J Neurol Sci       Date:  1980-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.